IMGN632 is a new CD123-targeting preclinical stage ADC that is a potential treatment for AML, myelodysplastic syndrome, B-cell acute lymphocytic leukemia and other CD123-positive malignancies. IMGN632 utilizes novel payload, linker and antibody technology and in preclinical models has demonstrated an impressive therapeutic window against CD123-positive malignancies.

IMGN632 is in Phase 1 testing.

In preclinical findings reported at the 21st Congress of the EHA, IMGN632 demonstrated potent in vitro and in vivo activity against AML cell lines and AML patient samples, including those with poor prognostic markers. IMGN632 was found to be active preclinically against AML cells with FLT-3 mutations, P53 mutations and with established multidrug resistance. Preclinical data reporting the prevalence of CD123-expression in ALL and the anti-leukemia activity of IMGN632 on ALL cells was reported at ASH 2017.

Last updated: January 2018

You are now leaving this website. If you would like to continue, click Continue.